Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets

Published
02 Sep 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$16.00
1.2% undervalued intrinsic discount
14 Aug
US$15.80
Loading
1Y
5.8%
7D
12.4%

Author's Valuation

US$16.0

1.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on10 Aug 25
Fair value Increased 9.71%

Sotera Health's consensus price target has increased to $15.75 as analysts reacted positively to a significant rise in net profit margin and a substantial decline in forward P/E, indicating improved profitability and valuation. What's in the News Sotera Health raised full-year 2025 earnings guidance, increasing expected net revenue growth to 4.5%–6.0% from 4.0%–6.0% on a constant currency basis.

Shared on08 May 25
Fair value Increased 2.41%

Shared on30 Apr 25
Fair value Decreased 2.00%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 3.77%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 1.74%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 2.87%

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on11 Mar 25
Fair value Increased 3.01%

AnalystConsensusTarget has increased revenue growth from 4.2% to 4.9%, increased profit margin from 11.6% to 16.2% and decreased future PE multiple from 39.3x to 26.6x.